MRNA Oct 2022 210.000 put
| Previous close | 80.81 |
| Open | 80.81 |
| Bid | 69.30 |
| Ask | 70.60 |
| Strike | 210.00 |
| Expiry date | 2022-10-21 |
| Day's range | 80.81 - 80.81 |
| Contract range | N/A |
| Volume | |
| Open interest | 242 |
- Motley Fool
Could This Send Moderna's Stock Soaring Back to $400?
Shares of Moderna (NASDAQ: MRNA) have been plummeting in recent months. As concerns shift from COVID-19 and onto inflation, investors have become less bullish on Moderna's stock. Omicron was a significant variant when it emerged in November, and that prompted Moderna to create a booster shot which targeted that variant.
- Motley Fool
3 Things About Moderna That Smart Investors Know
Prior to the pandemic, Moderna (NASDAQ: MRNA) was like many other small biotechs. In fact, for the full year of 2019, Moderna had only $60 million in revenue, entirely from collaborations and grants, and it posted a net loss of $514 million. As we know, Moderna's ability to rapidly produce a vaccine for the COVID-19 virus changed the financial prospects for the company and put it in a completely different position today.
- Zacks
Pfizer (PFE) Inks Deal With US Government for COVID Jab Supply
Pfizer (PFE) and partner BioNTech (BNTX) enter into an agreement with the government of the United States to supply 105 million doses of its mRNA-based COVID-19 vaccine.
